Stock Research for CLSN

CLSN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CLSN Stock Chart & Research Data

The CLSN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CLSN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CLSN Due diligence Resources & Stock Charts

The CLSN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CLSN Detailed Price Forecast - CNN Money CNN View CLSN Detailed Summary - Google Finance
Yahoo View CLSN Detailed Summary - Yahoo! Finance Zacks View CLSN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CLSN Trends & Analysis - Trade-Ideas Barrons View CLSN Major Holders - Barrons
NASDAQ View CLSN Call Transcripts - NASDAQ Seeking View CLSN Breaking News & Analysis - Seeking Alpha
Spotlight View CLSN Annual Report - CompanySpotlight.com OTC Report View CLSN OTC Short Report - OTCShortReport.com
TradeKing View CLSN Fundamentals - TradeKing Charts View CLSN SEC Filings - Bar Chart
WSJ View Historical Prices for CLSN - The WSJ Morningstar View Performance/Total Return for CLSN - Morningstar
MarketWatch View the Analyst Estimates for CLSN - MarketWatch CNBC View the Earnings History for CLSN - CNBC
StockMarketWatch View the CLSN Earnings - StockMarketWatch MacroAxis View CLSN Buy or Sell Recommendations - MacroAxis
Bullish View the CLSN Bullish Patterns - American Bulls Short Pains View CLSN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CLSN Stock Mentions - StockTwits PennyStocks View CLSN Stock Mentions - PennyStockTweets
Twitter View CLSN Stock Mentions - Twitter Invest Hub View CLSN Investment Forum News - Investor Hub
Yahoo View CLSN Stock Mentions - Yahoo! Message Board Seeking Alpha View CLSN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CLSN - SECform4.com Insider Cow View Insider Transactions for CLSN - Insider Cow
CNBC View CLSN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CLSN - OTC Markets
Yahoo View Insider Transactions for CLSN - Yahoo! Finance NASDAQ View Institutional Holdings for CLSN - NASDAQ


Stock Charts

FinViz View CLSN Stock Insight & Charts - FinViz.com StockCharts View CLSN Investment Charts - StockCharts.com
BarChart View CLSN Stock Overview & Charts - BarChart Trading View View CLSN User Generated Charts - Trading View




Latest Financial News for CLSN


Celsion Corporation to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 15, 2018
Posted on Thursday November 08, 2018

LAWRENCEVILLE, N.J, Nov. 08, 2018 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the.


Report: Exploring Fundamental Drivers Behind The ExOne, Switch, Monotype Imaging, Celsion, TrueCar, and Sandstorm Gold — New Horizons, Emerging Trends, and Upcoming Developments
Posted on Thursday October 25, 2018

NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.


Celsion Announces Progression-Free Survival Data From GEN-1 Phase I Immuno-Oncology Study of Patients with Stage III/IV Ovarian Cancer
Posted on Wednesday October 24, 2018

Median progression-free survival (PFS) in patients treated per protocol (n=13) was 24.3 months and was 17.1 months for the intent-to-treat population (n=18) for all dose cohorts, including three patients who dropped out of the study after 13 days or less, and two patients who did not receive full neoadjuvant chemotherapy (NAC) and GEN-1 cycles. The results from the OVATION I Study support continued evaluation of GEN-1 based on promising tumor response, as reported in the PFS data, and the ability for surgeons to completely remove visible tumor at debulking surgery.


Celsion Announces Publication Highlighting the Potential of Celsion's Gene-Mediated Immunotherapy to Improve Administration of IL-12 and Progression-Free Survival in Ovarian Cancer Patients
Posted on Monday October 22, 2018

Celsion Corporation (CLSN), an oncology drug development company, today announced that a program overview of the Company’s novel, immunotherapy agent GEN-1 was published in the peer-reviewed journal, Future Oncology. The article is co-authored by Premal H. Thaker, M.D., M.S., associate professor of obstetrics and gynecology at the Siteman Cancer Center at the Washington University School of Medicine in St. Louis, Mo. and principal investigator in Celsion’s GEN-1 development program. The publication outlines the DNA plasmid, gene-based concept and the key attributes supporting GEN-1’s mechanism of action characterized by local and persistent delivery of IL-12 and modulation of tumor microenvironment favoring immune stimulation.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.